Navigation Links
Dynogen Reports Positive Results in Phase 1B GERD Study

WALTHAM, Mass.--(BUSINESS WIRE)--Jun 7, 2007 - Dynogen Pharmaceuticals, Inc. reported positive results of its randomized, double-blind, placebo-controlled Phase 1b trial of DDP733 for gastroesophageal reflux disease (GERD). The study was designed to demonstrate proof-of-concept for DDP733 as a treatment for nocturnal GERD (NGERD). The 0.5 mg dose of DDP733 achieved statistical significance over placebo on the primary endpoint of reduction in the number of reflux events and was safe and well tolerated. Dynogen is planning to initiate a Phase 2 study of DDP733 in GERD patients in 2008.

DDP733 is an oral, partial agonist of the serotonin type 3 receptor (5-HT(3)), which Dynogen is developing for gastrointestinal conditions such as GERD and irritable bowel syndrome with constipation (IBS-c). In this translational medicine study, healthy volunteers were given a high fat meal to induce gastroesophageal reflux. Reflux events were measured by intraesophageal impedance (the electrical resistance that provides insight into the height and duration of a reflux episode).

"With this second set of positive proof-of-concept data for DDP733, following closely on the heels of our positive Phase 2 data for DDP733 in irritable bowel syndrome with constipation, we've unlocked the potential of this compound as a treatment for two distinct and underserved GI disorders," said Lee R. Brettman, M.D., Chief Executive Officer at Dynogen. "We estimate the peak sales for these indications to be in excess of a billion dollars each, reflecting the significant unmet medical need represented by these disorders. Dynogen has the opportunity to make a real difference in the quality of life of many patients suffering from these disorders."

"We designed this study with the dual goals of obtaining an indication of efficacy and establishing appropriate doses for our later-stage clinical study, and I am pleased to say we accomplished both
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Dynogens DDP733 Reduces Reflux in Phase 1b GERD Study
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Dynogen Reports Positive Results Phase GERD Study
(Date:1/23/2015)... 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is ... Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... fiduciary duties to shareholders. On January 21, ... reporting that Advaxis had misrepresented the clinical data for ...
(Date:1/23/2015)... , Jan. 23, 2015  Now available for sale, ... 7,849,611) support that prevents ankle sprains by cushioning the ... it fits securely around the outside of any shoe ... & comfort while still offering protection against sprains. With ...
(Date:1/23/2015)... , Jan. 23, 2015 Cord Blood America, Inc. ( ... or the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, ... today, and provides an update for shareholders detailing why a ... requested. Dear Shareholders, As we reflect ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... CRDC ) today announced that it will release ... 2011, on Monday, February 6, 2012, after the markets close. ... Eastern Time to discuss the financial results and provide an ... Call Details To access the live conference ...
... & Science business of Thomson Reuters announced an ... (IPEA). This partnership provides IPEA,s Direction of Sectorial ... (DISET) branch with access to the Newport ... and tools for sourcing global pharmaceutical ingredients. ...
Cached Medicine Technology:Cardica to Announce Fiscal 2012 Second Quarter Financial Results on Monday, February 6, 2012 2Thomson Reuters Helps Brazil's Institute for Applied Economic Research Identify New Generic Drug Opportunities 2
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... 22, 2015 Carinsurancesavings.biz has released a new ... and dismemberment insurance . , Purchasing an accidental death ... very advantageous. This type of rider provides benefits if the ... be considered a lesser form of life insurance. , ...
(Date:1/22/2015)... January 23, 2015 Recently, Weddingshe.com has added ... and has announced its highest annual revenues in the past ... its popular glamorous wedding dresses. , According to the sales ... wedding dress promotions for them in 2015. This point can ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
(Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining the importance of ... the costs of an auto insurance policy . , Clients ... prices for their vehicle insurance policies. The safety a vehicle offers ... Because of this, drivers should always carry a first aid ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... lung disease require more than brief smoking cessation ... Health & Science University Smoking Cessation Center report. ... in the online edition of Pulmonary and Critical ... of Physicians. , Although effective treatments for smoking ...
... Holdings,Inc. (NYSE: ZMH ; SWX: ZMH) announced today ... be broadcast live over the Internet on,Thursday, April 24, ... the quarterly results will be made available at 7:00 ... audio webcast can be accessed via Zimmer,s Investor Relations,website ...
... Care are Key Issues Facing State, LOS ANGELES, ... the first of several statewide forums on,Thursday, in which ... the,state,s healthcare infrastructure and potential solutions., The 2008 ... looming,shortage in healthcare workers, the wide disparities in quality ...
... those routinely excluded or under-represented, researchers say , , ... analysis of the American clinical trial process suggests ... routinely excluded or under-represented women, older people, minorities, ... "We,ve got a big problem," said Daniel S. ...
... RATON, Fla., April 1, 2008 Breckenridge announced,today that ... AG to,develop and manufacture a generic ANDA product. Under ... to the U.S. Food and Drug,Administration (FDA) for the ... currently shows U.S. sales of approximately $279 million, and,is ...
... primed them for chemical onslaught and exposed cancer cells, ... Fasting for two days before chemotherapy might protect cancer ... drugs by shielding healthy cells while dooming malignant cells ... of chemotherapy are one of the major obstacles in ...
Cached Medicine News:Health News:Smokers with lung disease need more than 'brief' intervention 2Health News:Report Claims Clinical Trials Miss Many Populations 2Health News:Report Claims Clinical Trials Miss Many Populations 3Health News:Report Claims Clinical Trials Miss Many Populations 4Health News:Fasting Before Chemo Protects Healthy Cells 2Health News:Fasting Before Chemo Protects Healthy Cells 3Health News:Fasting Before Chemo Protects Healthy Cells 4
... average 5:1 increase in usage time at all ... standard cannula. , ,The combination of the ... patients a superior alternative to liquid oxygen. , ... , ,NOTE: Each model ...
... An All-In-One Conserver., ,Offers an average 5:1 ... ,Allows the use of a standard cannula. ... and lightweight cylinders offers ambulatory oxygen patients a ... backed by a 2-year warranty. ...
... average 5:1 increase in usage time at all ... standard cannula. , ,The combination of the ... patients a superior alternative to liquid oxygen. , ... , ,NOTE: Each model ...
... an average 5:1 increase in usage time at ... a standard cannula. , ,The combination of ... oxygen patients a superior alternative to liquid oxygen. ... , ,NOTE: Each ...
Medicine Products: